POSTER: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14 (Encore), 4. Initiating Mepolizumab. 2. GSK?S SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. Vogelmeier CF, Boucot IH, Kerwin EM, et al. [Poster No. We're committed to doing the right thing for the people who count on us, and our culture will help you deliver what matters most - better and faster. POSTER: Utility of circulating tumor DNA in lung cancer clinical research and practice: systematic review and meta-analysis, 3. ORAL PRESENTATION: OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis, 2. Oncotarget. . The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles. Trends Cancer. Coyne, D et al. Registered in England and Wales No. CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. #News for #investors and #media: Today we announced the proposed acquisition of @BELLUSHealth, a clinical stage biopharmaceutical company that further strengthens our specialty medicines and respiratory pipeline. 2. In early stages, ~1/3 of people with the disease may not have any, but as it progresses, patients may experience a variety of symptoms that differ from person-to-person. It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial? 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at CAPTAIN: Effects of age as a continuous variable on asthma control. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis ?of REALITI-A? Our market sites can be reached by visiting our location selector. POSTER: Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment, 3. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. 2017;47(5):765-779. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1. Oncoimmunology. GSK3145095 is a small-molecule RIPK1 inhibitor. GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. Home | GSK US Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1?Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. POSTER: Niraparib Exposure-Response Relationship in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC), 3. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment (Encore), 3. This is our global website, intended for visitors seeking information on GSK's worldwide business. EU Medical Affairs Lead, Hematology. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanisms?the TGF-? GSK's Dr. Len Friedland, VP and Director of Scientific Affairs and Public Health for Sideline RSV Behind the science Oncology Gaining a deeper understanding of myelofibrosis - a rare blood cancer. GSK 4.2 Brentford Delivering the field medical and scientific engagement plan. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination With a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 6. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. All rights reserved. 5. 1. OX40 agonists and combination immunotherapy: putting the pedal to the metal. ", Explore our career opportunities all over the world, We strive to attract the best people and create an environment that, Every world-class scientist or inspiring leader had to start somewhere, We value what you bring and believe you can successfully transfer it to a, As we age, the #immunesystem weakens making us more vulnerable to #infectiousdiseases. Wu AC, McMahon PM, Mendelsohn A, et al. GSK3368715, a type 1 PRMT inhibitor, is being investigated in phase I trials for patients with diffuse large B-cell lymphoma and solid tumors. Fiore. McCreary G, Yawn BP, Linnell J, et al. 2019;7(4):559-571. 1. 3888792. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. Elaborating the Mechanism of PARP Synthetic Lethality in ATM Loss, 2. London, England, United Kingdom. 2. Rothnie K, Han X, Bengtson L, et al. 13. los inconvenientes que esto te pueda causar. Home | GSK US Medical Affairs Aydanos a proteger Glassdoor y demustranos que eres una persona real. www.vaers.hhs.gov to file a report, or call 1. 1. 6. Hellmich B, Neukirch K, Lukas M, et al. peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). POSTER: Subramanian S, et al. Fowler A, Kerstjens HAM, Bailes Z, et al. Hemoglobin Stability in the ASCEND-D and ND trials. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. PO0465, ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting ?2-agonist therapy. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. 1. 11. Work experience, placements and internships Join us as part of our work experience, placements and internships. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. We expect our organization to represent the population we serve by leveraging qualified, talented individuals who represent a variety of ethnicities, genders, disabilities, ages and sexual orientations. Please enable Cookies and reload the page. Strezova A et al. Poster No. Youll have the space to build and contribute to a high-performing team to make an impact on society. 5. Poster No. Gsk Medical Affairs jobs Sort by: relevance - date 55 jobs EU Medical Affairs Lead, Hematology GSK 4.1 Brentford TW8 Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Consider joining our contingent talent community for contract opportunities. Maximal Change in Erythropoietin in Hemodialysis ?Patients Receiving Daprodustat or Epoetin Alfa ?in the ASCEND-TD Trial, 9. GSK values your privacy and your trust is important to us. Bogart M, Han X, Bengtson L, et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. * Works in partnership with country teams to create and then implement global medical . DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 9. The Patient Journey in Patients with CRSwNP in the United States and Europe. The most rewarding part about working at GSK is that I know I can count on my team and leadership for guidance and support. 14. Zhang S, White J, Meeraus W, et al. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. 5. Bogart M, Bancroft T, Rothnie K, et al. Vogelmeier CF, Kerwin EM, Naya IP, et al. 2. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. [Poster No. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. Singh AK, et al. 2015;21(8):914-921. Corbridge T, Deb A, Packnett E, et al. Encore: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 16. Bjermer L, Maltais F, Vogelmeier CF, et al. POSTER: Differentiation of Niraparib and Olaparib Brain Penetration in a Mouse Brain Metastatic Tumor, 4. NY-ESO-ImmTAC (immune mobilizing monoclonal TCR against cancer [IMCnyeso]) is a bifunctional soluble high-affinity T-cell receptor (TCR) specific for NY-ESO-1 that also engages the CD3 receptor on T cells. Criner GJ, Barnes N, Brusselle G, et al. Select a product first, and then enter a keyword for your topic of interest. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Can Recombinant Zoster Vaccine Administration Decrease the Use of HZ-Related Pain Medication Across Randomized Controlled Studies? Rationale for anti-OX40 cancer immunotherapy. POSTER: Meta-analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma (2L+ mSS), 5. ENCORE: Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma, 18. 4. Chupp G, Heaney L, Price R, et al.Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study (Poster No. 1. [Oral presentation available here; Abstract A4212]. 2018;9:1072. doi:10.3389/fimmu.2018.01072. Gsk Medical Jobs in London | Indeed.com Upload your CV and easily apply to jobs from any device! 2017;35(15):suppl TPS3113. Calverley PMA, Celli BR, Crim C, et al. 1. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. 13. 1. Achieving SLE Disease Control or LLDAS and Lower Organ Damage Rates, 2. Gibbons D, Marijam A, Morel Symons J, et al. The estimated total pay for a Medical Science Liaison at GSK is $234,850 per year. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab, 1. POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK?859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC), 1. and Physicians? ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. 2. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. P699; Abstract A1814]. Ferguson GT, Brown N, Compton C, et al. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Poster No. This site is intended for US Patients or Caregivers. Trade marks are owned by or licensed to the GSK group of companies. POSTER: Physician-reported Patient Involvement in 1L Ovarian Cancer Treatment, Including Maintenance, in the US and Europe: A Real-World Chart Review Analysis (2017?2020), 1. Singh AK, et al. Poster No. Blood. Brett S, Yadavilli S, Seestaller-Wehr L, et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. Dostarlimab is being investigated as a monotherapy in DNA mismatch repair?deficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients? Curr Opin Pharmacol. There is always room to grow as a professional and own your career path. 3. Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US? POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. ?Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. 1. 347). GSK US Medical Affairs Scientific Director, Specialty Pipeline Durham, NC 30d+ $95K-$138K Per Year (Glassdoor est.) Chandler R et al. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgren?s Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. 2016;7(41):67532-67550. 178 Medical Affairs Jobs in London, England, United Kingdom (9 new) Regulatory Affairs Officer / RAQA Officer Hays Uxbridge, England, United Kingdom Be an early applicant 4 weeks ago. Singer D et al. Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. McCormack E, Adams KJ, Hassan NJ, et al. Jobs; Companies; . POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Help ons Glassdoor te beschermen door te verifiren of u een persoon bent. 1. The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the GARNET Trial, 1. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. Ramesh N, Hegewald M, Maselli DJ, et al. PD-L1 is expressed by many tumor types and is linked to poor clinical outcomes in a variety of cancers. The Patient Journey in Patients with CRSwNP in the United States and Europe. 5. Dransfield MT, Halpin DMG, Han MK, et al. Maximal Change in Erythropoietin in Hemodialysis ?Patients Receiving Daprodustat or Epoetin Alfa ?in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of ?Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial. GSK Careers Apply For our most senior roles we start with a diverse shortlist of qualified candidates, including ethnically diverse representation (defined by country). Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Poster No. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. This information does not take the place of talking with your doctor. P1045; Abstract A5050]. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. GSK Medical Science Liaison Salaries | Glassdoor A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States (ESGO Encore), 3. Keeley T, et al. EU Medical Affairs Lead, Hematology - jobs.gsk.com POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. and PD-L1, in patients with pretreated biliary tract cancer, 11. receptor II (TGF-?RII or TGF-? Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. Temporary assignment- Lead team of 150 people, including all . 2004;199(1):91-98. Knudson KM, Hicks KC, Luo X, Chen J-Q, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGF trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Mafodotin delivered to BCMA-expressing malignant cells inhibits microtubule polymerization, resulting in immune-independent apoptosis that is accompanied by release of markers of immunogenic cell death (ICD), which may contribute to an adaptive immune response. [Poster No. Verhamme K, de Ridder M, Webb D, et al. 12. Medical Affairs Gsk Jobs, Employment | Indeed.com Today's top 149 Gsk Medical Affairs jobs in United States. Nat Med. message, please email Patients? Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta?) Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. enviando un correo electrnico a Cancer Immunol Immunother. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. P1445. Bogart M, Bunner S, Johnson MG, et al. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de and/or LAGE-1a?positive solid tumors, NSCLC, and relapsed/refractory multiple myeloma. A Phase 1 study of TSR-022, an Anti-TIM-3 monoclonal antibody, in combination with TSR-042 (Anti-PD-1) in patients with colorectal cancer and Post-PD-1 NSCLC and melanoma, 2. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility. www.fda.gov/medwatch. and Physicians? Trade marks are owned by or licensed to the GSK group of companies. 2001-2023 GSK plc. Sule N, Fowler A, Kerstjens HA, et al. Disculpa Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. Als u dit bericht blijft zien, stuur dan een e-mail [Poster No. 22 Gsk Medical Affairs jobs in London, England, United Kingdom (2 new) POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. We set an aspirational goal here in the US. Prez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. Mar 2022 - Present1 year 2 months. Poster No. 10. BCMA is essential for the survival of long-lived bone marrow plasma cells. The estimated total pay for a Medical Affairs at GSK is $206,808 per year. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). 2017;31(2):101-126. CD96 is an immune checkpoint protein expressed on T cells and natural killer (NK) cells in multiple tumor types. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. 1. GSK is committed to the discovery and development of new vaccines and oncology and hematology compounds that leverage patient-driven science to deliver improved outcomes for more patients. perspective on the burden of Hypereosinophilic Syndrome. Busse W, Chupp G, Stanaland M, et al. 2. P806; Abstract A4295]. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. om ons te informeren over dit probleem. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. POSTER: Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first-line maintenance therapy, 1.
An Ancestral Species Of Duck Has A Varied Diet Quizlet,
Michigan Stadium Suites,
Warwick Football Roster,
Articles G
French 
English